Afficher la notice abrégée

dc.contributor.authorHuang, Yazhong
dc.contributor.authorKnouse, Kyle W.
dc.contributor.authorQiu, Shenjie
dc.contributor.authorHao, Wei
dc.contributor.authorVantourout, Julien C.
dc.contributor.authorZheng, Bin
dc.contributor.authorMercer, Stephen E.
dc.contributor.authorLopez-Ogalla, Javier
dc.contributor.authorNarayan, Rohan
dc.contributor.authorOlson, Richard E.
dc.contributor.authorBlackmond, Donna G.
dc.contributor.authorEastgate, Martin D.
dc.contributor.authorSchmidt, Michael A.
dc.contributor.authorMcDonald, Ivar M.
dc.contributor.authorBaran, Phil S.
dc.contributor.authorMuñoz Padial, Natalia 
dc.date.accessioned2025-01-30T09:36:43Z
dc.date.available2025-01-30T09:36:43Z
dc.date.issued2021-09-10
dc.identifier.citationScience, 2021, 373, 1265–1270es_ES
dc.identifier.urihttps://hdl.handle.net/10481/101157
dc.description.abstractThe promise of gene-based therapies is being realized at an accelerated pace, with more than 155 active clinical trials and multiple U.S. Food and Drug Administration approvals for therapeutic oligonucleotides, by far most of which contain modified phosphate linkages. These unnatural linkages have desirable biological and physical properties but are often accessed with difficulty using phosphoramidite chemistry. We report a flexible and efficient [P(V)]–based platform that can install a wide variety of phosphate linkages at will into oligonucleotides. This approach uses readily accessible reagents and can install not only stereodefined or racemic thiophosphates but any combination of (S, R or rac)–PS with native phosphodiester (PO2) and phosphorodithioate (PS2) linkages into DNA and other modified nucleotide polymers. This platform easily accesses this diversity under a standardized coupling protocol with sustainably prepared, stable P(V) reagents.es_ES
dc.description.sponsorshipWe thank D.-H. Huang and L. Pasternack (Scripps Research) for assistance with NMR spectroscopy; J. Chen (Automated Synthesis Facility, Scripps Research) for purification of compounds and acquisition of HRMS data; A. L. Rheingold, C. E. Moore, and M. Gembicky (UCSD) for x-ray analysis; and S. Mukherjee (BMS) for calculating the process mass intensity. Funding: This work was supported by Bristol Myers Squibb, NIGMS (GM106210), NIH (grant number GM-118176), Marie Skłodowska-Curie Global Fellowships (749359-EnanSET, N.M.P) within the European Union research and innovation framework program (2014-2020), and the NSF SURF Program (TSRI, R.N).es_ES
dc.language.isoenges_ES
dc.publisherAmerican Association for the Advancement of Science: AAAS, USA.es_ES
dc.titleA P(V) platform for oligonucleotide synthesises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1126/science.abi9727
dc.type.hasVersionAMes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée